|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:John_Evans
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
gptkb:beta-thalassemia
sickle cell disease
rare genetic diseases
therapeutics for genetic diseases
|
|
gptkbp:foundedYear
|
2017
|
|
gptkbp:founder
|
gptkb:David_R._Liu
gptkb:Feng_Zhang
gptkb:John_Evans
gptkb:J._Keith_Joung
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Beam Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
February 2020
|
|
gptkbp:notableCollaboration
|
gptkb:Pfizer
gptkb:Verve_Therapeutics
|
|
gptkbp:notableInvestment
|
gptkb:F-Prime_Capital
gptkb:GV_(Google_Ventures)
gptkb:8VC
gptkb:ARCH_Venture_Partners
|
|
gptkbp:notableProduct
|
gptkb:BEAM-101
gptkb:BEAM-201
gptkb:BEAM-301
gptkb:BEAM-302
|
|
gptkbp:numberOfEmployees
|
approximately 400 (2023)
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:specializesIn
|
gene editing
base editing
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:BEAM
|
|
gptkbp:technology
|
CRISPR base editing
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_BEAM
|
|
gptkbp:website
|
https://www.beamtx.com/
|
|
gptkbp:bfsParent
|
gptkb:David_R._Liu
gptkb:Feng_Zhang
|
|
gptkbp:bfsLayer
|
4
|